Lupin launches cardiovascular drug in US market

Lupin :  It launched generic heart rivaroxaban tablets in the US market after it received approval from the US Food and Drug Administration (US FDA).

According to the company, the Rivaroxaban Tablets USP, 2.5 mg tablets are a bioequivalent of Janssen Pharmaceuticals’ Xarelto® Tablets, 2.5 mg, which generated an estimated $446 million in sales annually in the US.

Shares of Lupin closed at Rs 2,029.00, up 0.52% on the National Stock Exchange (NSE). However, it announced the new drug launch after market hours.

The newly launched drug will be used to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD). Additionally, it will help “to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularisation due to symptomatic PAD,” the company said in a regulatory filing.

Lupin share performance

Lupin shares gained 6.58% over the week but have lost 8.45% since the beginning of February. The script has fallen 13.83% on a year-to-date basis.

It hit its 52-week high of Rs 2,402.90 on January 2, 2025 and low of Rs 1,493.30 on June 4, 2024

The pharmaceutical company has a total market cap of Rs 92,632.16 crore as of March 7, 2025, on the NSE.

About Lupin

Headquartered in Mumbai, Lupin is a global pharmaceutical company with operations spread across 100 markets. It specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients.

Related Posts

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

The Court observed that the alleged short supply of one tablet, coupled with the collection of ₹1.12, did not establish that the accused had sold the drug at a price…

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

MEERUT/SHIMLA: An illegal pharmaceutical factory allegedly manufacturing counterfeit medicines used to treat epilepsy, diabetes, typhoid and other ailments using substances such as chalk and lactose was busted in Himachal Pradesh’s…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital